CDC authorizes COVID-19 vaccines for children 5-11 years of age
Author
Blaire Bryant
Upcoming Events
Related News
Key Takeaways
On November 2, the Centers for Disease Control and Prevention (CDC) approved the use of COVID-19 vaccines for children aged 5-11 following the Food and Drug Administration’s (FDA) recommendation. The CDC’s endorsement follows the FDA’s recommendation on October 29 to authorize emergency use of the Pfizer-BioNTech COVID-19 vaccine to include children 5-11 years of age.
The FDA’s decision comes after it was determined the vaccine was approximately 91 percent effective in preventing COVID-19 in children 5-11 years of age. Children within this age group account for 39 percent of COVID-19 cases in individuals younger than 18 years of age across the nation. An ongoing study discovered no serious side effects in approximately 3,100 children aged 5-11 who received the COVID-19 vaccine.
On October 14, the CDC released a Pediatric COVID-19 Vaccination Operational Planning Guide, which highlights key differences between adult and adolescent vaccination programs and those that are designed for children. The National Association of County and City Health Officials (NACCHO) has provided a summary of the guide and pulled out high-level considerations for county health departments, as key components of pediatric COVID-19 vaccination planning in local communities.
As key providers of local public health services and frontline service providers for the medically vulnerable, counties have supported over 192 million vaccinations in the United States to date and will continue to play an essential role in the administration of COVID-19 vaccines and boosters. For more information on how county health facilities can prepare for the distribution of COVID-19 vaccines for children, and COVID-19 boosters, see NACo’s COVID-19 Vaccine Distribution Toolkit.
ADDITIONAL RESOURCES
Resource
COVID-19 Vaccine Toolkit for Counties
Related News
U.S. Department of Health and Human Services announces major restructuring
On March 27, the U.S. Department of Health and Human Services (HHS) announced a sweeping reorganization that will consolidate agencies, shift key programs under a new framework and eliminate thousands of positions. This change brings HHS in line with President Trump's Executive Order, “Implementing the President’s ‘Department of Government Efficiency’ Workforce Optimization Initiative.”
U.S. Department of Health and Human Services moves to reduce public comment in rulemaking
On February 28, the U.S. Department of Health and Human Services (HHS) announced a policy change limiting public comment opportunities to only those required by law. Published in the Federal Register on March 3, the decision rescinds the “Richardson Waiver,” a 1971 directive from then-HHS Secretary Elliot Richardson that encouraged broader public input on regulations related to public benefits, grants and healthcare policies.
U.S. Department of Health and Human Services renews Public Health Emergency Declaration to address national opioid crisis
On March 18, the U.S. Department of Health and Human Services (HHS), under the direction of Secretary Robert F. Kennedy, Jr. renewed the public health emergency (PHE) declaration to address the ongoing opioid crisis, extending critical federal support for coordination, treatment expansion and research efforts. While overdose deaths have declined by 25.5 percent over the past year, synthetic opioids like fentanyl continue to drive fatalities, with approximately 150 Americans dying daily from overdoses.